Get Genmab A/S alerts:Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) – Research analysts at William Blair increased their FY2025 earnings estimates for shares of Genmab A/S in a note issued to investors on Monday, September 29th. HC Wainwright increased their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Wall Street Zen raised shares of Genmab A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Finally, Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock.